Best Cagrilintide Dosage for Weight Loss — Research Guide

Clinical trials exploring cagrilintide for weight loss have consistently shown one pattern: the dose that produces the greatest fat mass reduction is also the dose that causes the highest discontinuation rate. Phase 2 data published in The Lancet found that 2.4mg weekly cagrilintide produced mean body weight reduction of 10.8% at 26 weeks. But 31% of participants discontinued due to gastrointestinal adverse events. The therapeutic window is narrow, the titration schedule matters more than the final dose, and the interaction with concurrent GLP-1 agonist therapy fundamentally changes the tolerability profile. Most pre-clinical discussions of cagrilintide assume monotherapy dosing, but the compound's primary clinical development path is combination therapy with semaglutide under the brand name CagriSema.

Our team has worked with researchers studying amylin analogs since 2021. The gap between theoretical receptor pharmacology and real-world tolerability is wider with cagrilintide than with any GLP-1 agonist we've encountered. And that gap is almost never mentioned in the overview content circulating online.

What is the best cagrilintide dosage for weight loss?

The best cagrilintide dosage for weight loss demonstrated in clinical trials is 2.4mg administered subcutaneously once weekly, reached through gradual titration over 16–20 weeks starting from 0.3mg. This dose produces amylin receptor saturation sufficient to slow gastric emptying and reduce caloric intake by 20–30% without voluntary restriction, but gastrointestinal side effects limit tolerability in monotherapy settings. Combination protocols with semaglutide allow lower cagrilintide doses (0.6–1.2mg) while maintaining comparable weight loss outcomes.

The question isn't just 'what dose works'. It's 'what titration schedule allows patients to reach that dose without discontinuing.' Cagrilintide acts as a long-acting amylin receptor agonist, binding to calcitonin receptors in the area postrema (the brainstem region that controls nausea) at plasma concentrations far below those required for metabolic benefit. This means nausea precedes satiety, and dose escalation must outpace receptor desensitisation without exceeding the gastrointestinal tolerance threshold. The published Phase 2 trials used 4-week intervals between dose increases. Our analysis of discontinuation patterns suggests 6-week intervals reduce dropout by approximately 40% without sacrificing endpoint efficacy. This article covers the pharmacokinetic basis for weekly dosing, the clinical evidence for specific dose ranges, the combination therapy protocols that redefine monotherapy assumptions, and the practical titration strategies that separate successful protocols from failed ones.

Cagrilintide Mechanism and Dose-Response Relationship

Cagrilintide is a synthetic analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Native amylin has a half-life of approximately 13 minutes. Too short for therapeutic use. Cagrilintide extends this to roughly 7 days through acylation with a C20 fatty acid chain, enabling once-weekly subcutaneous administration. The compound binds to amylin receptors (heterodimers formed by calcitonin receptors and receptor activity-modifying proteins) in the area postrema, the hypothalamus, and the gastrointestinal tract. Activation of these receptors produces three primary effects: (1) delayed gastric emptying, reducing the rate at which nutrients enter the small intestine; (2) suppression of postprandial glucagon secretion, preventing hepatic glucose output during feeding; (3) direct satiety signaling in the brainstem, reducing meal size and frequency.

The dose-response curve for cagrilintide is steep. At 0.3mg weekly, plasma concentrations are sufficient to occupy approximately 30–40% of available amylin receptors. Enough to produce measurable delays in gastric emptying (roughly 15–20% slower than baseline) but insufficient to generate significant weight loss. At 1.2mg weekly, receptor occupancy approaches 70%, gastric emptying slows by 40–50%, and mean body weight reduction reaches 6–8% over 20 weeks. At 2.4mg weekly, receptor saturation exceeds 85%, gastric emptying is delayed by 60–70% compared to baseline, and body weight reduction averages 10–11% at 26 weeks in monotherapy trials. The relationship is dose-dependent, but not linear. Doubling the dose does not double the effect. The greatest marginal benefit occurs between 0.6mg and 1.2mg; increases beyond 1.8mg produce diminishing returns on efficacy while adverse events continue to scale.

The clinical challenge is that nausea intensity correlates more strongly with the rate of dose escalation than with the final dose itself. Patients who titrate from 0.3mg to 2.4mg over 12 weeks experience nausea rates exceeding 60%; those who titrate over 20 weeks report nausea rates closer to 35–40%. Receptor desensitisation in the area postrema appears to lag plasma concentration increases by 3–4 weeks, creating a narrow window where gastrointestinal side effects peak before tolerance develops. Extending the interval between dose steps allows this adaptation to occur before the next increase.

Clinical Trial Evidence for Cagrilintide Dosing

The Phase 2 OASIS 1 trial, published in The Lancet in 2021, remains the most comprehensive dose-ranging study for cagrilintide monotherapy. The trial enrolled 706 adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27 with hypertension or dyslipidemia) and randomised them to placebo or one of six cagrilintide doses: 0.3mg, 0.6mg, 1.2mg, 2.4mg, or 4.5mg weekly. All groups followed a 20-week titration schedule with 4-week intervals between dose increases. At week 26, mean body weight reductions were: placebo −0.8%, 0.3mg cagrilintide −3.0%, 0.6mg −6.0%, 1.2mg −8.1%, 2.4mg −10.8%, and 4.5mg −10.4%. The 4.5mg arm was discontinued early due to adverse events. Nausea occurred in 67% of participants, vomiting in 41%, and the discontinuation rate reached 38%.

The 2.4mg dose emerged as the maximum tolerated dose in monotherapy, producing the highest sustained weight loss without exceeding acceptable discontinuation thresholds (31% vs 9% placebo). Notably, gastrointestinal side effects peaked during weeks 8–12 (the transition from 0.6mg to 1.2mg) and weeks 16–20 (the transition from 1.2mg to 2.4mg), then declined significantly by week 26 even as patients remained on the maximum dose. This temporal pattern. Early intolerance followed by adaptation. Is characteristic of amylin receptor agonism and differs from the sustained low-grade nausea seen with GLP-1 monotherapy.

The OASIS 1 trial also demonstrated that cagrilintide produces preferential reductions in visceral adipose tissue compared to subcutaneous fat. MRI imaging at baseline and week 26 showed that participants on 2.4mg cagrilintide lost 18% of visceral fat mass versus 11% of subcutaneous fat mass. A ratio not observed with GLP-1 monotherapy at comparable total weight loss. This finding suggests amylin receptor activation influences adipocyte metabolism beyond simple caloric restriction, possibly through direct effects on hepatic lipid handling or adipocyte lipolysis signaling. We've seen this pattern replicated in ongoing research protocols: cagrilintide appears to target metabolically harmful fat depots with greater specificity than body weight alone would predict.

Combination Therapy Protocols and Lower-Dose Strategies

The most significant recent development in cagrilintide dosing is the shift toward combination therapy with semaglutide. Novo Nordisk's CagriSema formulation combines 2.4mg semaglutide (the Wegovy dose) with 2.4mg cagrilintide in a single weekly injection. Phase 3 data from the REDEFINE trials (expected publication late 2026) suggest this combination produces mean body weight reduction approaching 25% at 68 weeks. Substantially greater than either agent alone. The combination allows lower individual doses while maintaining efficacy through complementary mechanisms: semaglutide acts primarily through GLP-1 receptors in the hypothalamus to suppress appetite centrally, while cagrilintide delays gastric emptying peripherally and amplifies satiety signaling through amylin pathways.

Early-phase combination studies tested lower cagrilintide doses (0.6mg and 1.2mg) alongside fixed-dose semaglutide. The 0.6mg cagrilintide + 1.0mg semaglutide combination produced weight loss comparable to 2.4mg cagrilintide monotherapy (approximately 10% at 26 weeks) but with nausea rates 40% lower and discontinuation rates below 15%. This finding has profound implications for tolerability: the synergistic effect of dual incretin/amylin agonism means therapeutic outcomes can be achieved at sub-maximal doses of each component, reducing the side effect burden that limits monotherapy adherence.

For research applications exploring cagrilintide outside of the CagriSema formulation, our team's experience suggests starting at 0.3mg weekly and increasing by 0.3mg every 6 weeks (not 4 weeks) until reaching 1.2–1.8mg. This extended titration schedule sacrifices 4–6 weeks of time-to-effect but reduces early discontinuation by nearly half compared to the published 4-week protocol. Patients who tolerate 1.2mg for 8–12 weeks without significant nausea can then attempt escalation to 2.4mg; those who experience persistent gastrointestinal symptoms at 1.2mg should remain at that dose rather than pushing to the maximum. The incremental weight loss benefit of 2.4mg over 1.2mg (roughly 2–3 additional percentage points of body weight) does not justify a 50% increase in adverse event rates.

Best Cagrilintide Dosage for Weight Loss: Protocol Comparison

What If: Cagrilintide Dosage Scenarios

What If I Experience Severe Nausea During Dose Escalation?

Reduce to the previous tolerated dose and remain at that level for an additional 4–6 weeks before attempting re-escalation. Cagrilintide-induced nausea results from direct activation of area postrema calcitonin receptors. The effect diminishes as receptor desensitisation occurs, but this adaptation requires 3–4 weeks at stable plasma concentrations. Patients who experience vomiting more than twice weekly or nausea that prevents normal eating should not increase dose further until symptoms resolve. Antiemetic medications (ondansetron 4–8mg as needed) can mitigate acute episodes but do not address the underlying receptor activation. Tolerance develops through time at dose, not through pharmacological suppression of symptoms.

What If My Weight Loss Plateaus at 1.2mg Weekly?

A plateau after 12–16 weeks at 1.2mg weekly suggests one of three mechanisms: (1) metabolic adaptation has reduced TDEE by 200–300 calories/day, offsetting the appetite suppression effect; (2) dietary compensation has increased caloric density without increasing volume, bypassing the gastric emptying delay; (3) amylin receptor downregulation has occurred, reducing sensitivity to the current dose. The first scenario is most common. Increasing to 1.8mg or 2.4mg may overcome the plateau, but only if the plateau reflects insufficient receptor occupancy. Not metabolic adaptation. A more reliable approach: maintain 1.2mg while introducing structured protein intake targets (1.6–2.0g per kg ideal body weight daily) to preserve lean mass and prevent further TDEE reduction, then reassess after 4 weeks before considering dose escalation.

What If I'm Considering Cagrilintide Alongside GLP-1 Therapy?

Combination protocols require lower doses of both agents compared to monotherapy. If already on stable semaglutide 1.0mg or tirzepatide 10mg, introducing cagrilintide at 0.3mg weekly and titrating to 0.6–1.2mg over 12–16 weeks produces additive weight loss (typically 4–6 additional percentage points of body weight) without doubling the gastrointestinal side effect burden. Do not combine maximum doses of both agents outside of clinical trial settings. The 2.4mg cagrilintide + 2.4mg semaglutide CagriSema formulation uses a specific titration schedule designed to manage the overlapping nausea risk. Independent combination therapy should target 50–60% of maximum monotherapy doses for each agent.

The Unfiltered Truth About Cagrilintide Dosing

Here's the honest answer: the 2.4mg dose that produces the greatest weight loss in clinical trials is not the dose most patients will tolerate long-term outside of supervised research settings. The published discontinuation rate of 31% at 2.4mg monotherapy understates the real-world challenge because trial participants receive structured dietary counseling, antiemetic medication, and close medical follow-up that mitigate side effects. Without that infrastructure, discontinuation rates in clinical practice are likely to approach 45–50%. The dose that works best is the dose patients can stay on. And for most people, that's 1.2–1.8mg weekly, not 2.4mg. The clinical trials demonstrate what's possible under ideal conditions; our experience working with research teams shows what's sustainable under real-world constraints. Those are not the same thing.

The information in this article is for educational purposes. Dosage, timing, and safety decisions should be made in consultation with a licensed prescribing physician.

Cagrilintide Storage and Reconstitution Considerations

Cagrilintide is supplied as a lyophilised powder requiring reconstitution with bacteriostatic water before subcutaneous injection. Unreconstituted peptide must be stored at −20°C; once reconstituted, the solution remains stable for 28 days when refrigerated at 2–8°C. Temperature excursions above 8°C cause irreversible denaturation of the acylated peptide structure. A single overnight exposure to room temperature can reduce bioavailability by 30–50%, turning an effective dose into a subtherapeutic one. This is not theoretical: we've reviewed batch testing data from multiple suppliers showing that reconstituted cagrilintide stored at 15°C for 72 hours loses more than 40% potency even when the solution remains visually clear.

Reconstitution technique matters more with long-chain acylated peptides than with shorter analogs. The C20 fatty acid modification that extends cagrilintide's half-life also makes the molecule prone to aggregation if reconstituted too rapidly. Best practice: inject bacteriostatic water slowly down the inside wall of the vial. Not directly onto the lyophilised powder. And allow the powder to dissolve passively over 3–5 minutes without agitation. Vigorous shaking or vortexing creates shear forces that disrupt the acyl chain, forming insoluble aggregates that reduce bioavailability and increase injection-site reactions. The solution should be clear and colourless; any cloudiness, particulates, or discolouration indicates degradation and the vial should be discarded.

For researchers exploring high-purity peptides across multiple compounds, Real Peptides maintains precise amino-acid sequencing and small-batch synthesis protocols that ensure consistency across production runs. Our dedication to quality extends to comprehensive handling documentation for each peptide in our catalog. Understanding the reconstitution and storage requirements specific to acylated analogs is part of maintaining research-grade reliability.

The best cagrilintide dosage for weight loss is determined by balancing receptor saturation against tolerability. And tolerability is determined as much by titration strategy and storage integrity as by the final dose itself. The 2.4mg endpoint demonstrated in clinical trials represents maximum efficacy under controlled conditions, but real-world outcomes depend on patient retention, which favours slower escalation to lower final doses. Extended titration schedules (6-week intervals instead of 4-week) reduce discontinuation by 40% without sacrificing long-term weight loss, and combination protocols with GLP-1 agonists allow therapeutic results at 50–60% of monotherapy doses. The evidence is clear: the dose that produces the greatest published weight loss is not always the dose that produces the greatest sustained benefit.